Carregant...
Repression of AXL expression by AP-1/JNK blockage overcomes resistance to PI3Ka therapy
AXL overexpression is a common resistance mechanism to anticancer therapies, including the resistance to BYL719 (Alpelisib) — the p110α isoform specific inhibitor of phosphoinositide 3-kinase (PI3K) — in esophagus squamous cell carcinoma (ESCC) and head and neck squamous cell carcinoma (HNSCC). Howe...
Guardat en:
| Publicat a: | JCI Insight |
|---|---|
| Autors principals: | , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
American Society for Clinical Investigation
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6538319/ https://ncbi.nlm.nih.gov/pubmed/30860495 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.125341 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|